Osteoarthritis is a degenerative joint disease affecting cartilage, subchondral bone, and periarticular tissues, causing pain, stiffness, and functional limitation. It is a leading cause of disability in older adults.
Researchers developed a cell-free cartilage scaffold that guides bone regeneration without strong immune reactions. The off-the-shelf graft, tested in animals, could replace costly patient-specific grafts. Human trials are being prepared.
MEDIPOST treated the first U.S. participant in a Phase III trial of its umbilical cord blood-derived MSC therapy for knee osteoarthritis. The FDA agreed the single pivotal study, supported by prior trials in South Korea and Japan, can support a planned BLA filing.
A UTSW study shows post-exertion gait analysis can reveal lingering deficits in concussed youths, while UCLA Health expands biologic and regenerative therapies for athletes. These advances aim to improve recovery and return-to-play decisions.
FDA approved Medtronic's Hugo for urologic procedures; a new robotic and AR system showed high precision in jaw surgery; East and Central Africa saw its first robotic-assisted knee replacements.
Amgen shares have fallen 12.6% in three months despite relatively solid Q1 results, while Novo Nordisk maintains a 54.6% global GLP-1 market share. Both companies face pipeline competition and pricing pressures.
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
Animal health markets are projected to expand in 2026, led by animal biotechnology at $34.6 billion to $36.19 billion and continued growth in veterinary antibiotics. Demand is being driven by companion animal care, livestock health, biologics R&D, and tighter oversight of antibiotic use.
Cynata raised $1.5 million through a placement at $0.25 a share ahead of Phase 3 osteoarthritis and Phase 2 aGvHD trial readouts due in May and June 2026. Its aGvHD study has completed the 100-day primary evaluation period for all 65 participants.
The healthcare 3D printing market is projected to reach $14.6 billion by 2033, while the bioinks market is anticipated to reach USD 683.6 million. Growth is tied to personalised medical solutions, tissue engineering, drug discovery, and advances in biomaterials.
Five intra-articular gene therapy platforms for knee osteoarthritis are in human trials in the US, while India prepares regulatory guidelines for mRNA, gene and cell therapies to accelerate innovation.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779629 |
Efficacy & Safety of Fluoroquinolone-Based Brucellosis Regimens (BRUCE) |
NOT_YET_RECRUITING | NA |
| NCT07755579 |
Effect of Autologous Ear Cartilage Micrografting in Knee Osteoarthritis |
ACTIVE_NOT_RECRUITING | NA |
| NCT07751263 |
15-Hydroxyprostaglandin Dehydrogenase in Osteoarthritis and Ankylosing Spondylitis |
NOT_YET_RECRUITING | |
| NCT07720024 |
Comparison of Medial Knee Pain Between Patients With and Without Preoperative Tibia Vara Underging Mobile-bearing Unicompartmental Knee Arthroplasty |
COMPLETED | |
| NCT07710404 |
Effectiveness of Joint Distraction Versus Passive End Range Overpressure in Osteoarthritis: |
COMPLETED | NA |
| NCT07701174 |
Weighted Dangling Exercises vs Vastus Medialis Oblique Muscle Neuromuscular Stimulation for Knee Osteoarthritis |
RECRUITING | NA |
| NCT07696195 |
The Effectiveness of Resistance Training for Patients With Degenerative Arthritis After Surgery |
COMPLETED | NA |
| NCT07660081 |
Effects of Acetyl L-Carnitine Supplementation on Clinical, Metabolic and Inflammatory Symptoms in Obese, Diabetic, Postmenopausal Women With Osteoarthritis |
ACTIVE_NOT_RECRUITING | NA |
| NCT07630896 |
Post-op Prednisone and Glucose Monitoring in TKA |
NOT_YET_RECRUITING | PHASE4 |
| NCT07617233 |
Blood Cell Ratios as Predictors of Response to Platelet-Rich Plasma in Knee Osteoarthritis |
NOT_YET_RECRUITING |
